miR-197-5p increases Doxorubicin-mediated anticancer cytotoxicity of HT1080 fibrosarcoma cells by decreasing drug efflux

Restoration of microRNA‐197 expression suppresses oncogenicity in fibrosarcoma through negative regulation of RAN

(2020) Neha Jain et al.   IUBMB LIFE

The role and mechanisms of action of microRNAs in cancer drug resistance

(2019) Wengong Si et al.   Clinical Epigenetics

miRNA-192-5p impacts the sensitivity of breast cancer cells to doxorubicin via targeting peptidylprolyl isomerase A

(2019) Yi Zhang et al.   KAOHSIUNG JOURNAL OF MEDICAL SCIENCES

miR‐197‐5p inhibits sarcomagenesis and induces cellular senescence via repression of KIAA0101

(2019) Neha Jain et al.   MOLECULAR CARCINOGENESIS

MiR-770 suppresses the chemo-resistance and metastasis of triple negative breast cancer via direct targeting of STMN1

(2018) Yaming Li et al.   Cell Death & Disease

Protective effect of dioscin against doxorubicin-induced cardiotoxicity via adjusting microRNA-140-5p-mediated myocardial oxidative stress

(2018) Lisha Zhao et al.   Redox Biology

Current diagnostics and treatment of fibrosarcoma –perspectives for future therapeutic targets and strategies

(2017) Daniela Augsburger et al.   Oncotarget

Noncoding RNA in drug resistant sarcoma

(2017) Xiaoyang Li et al.   Oncotarget

MiR-101 and doxorubicin codelivered by liposomes suppressing malignant properties of hepatocellular carcinoma

(2017) Fei Xu et al.   Cancer Medicine

Regulation of multidrug resistance by microRNAs in anti-cancer therapy

(2017) Xin An et al.   Acta Pharmaceutica Sinica B

miR-197: A novel biomarker for cancers

(2016) Dan-dan Wang et al.   GENE

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

(2016) William D Tap et al.   LANCET

miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer

(2016) Y Hu et al.   Cell Death & Disease

MicroRNA-197 influences 5-fluorouracil resistance via thymidylate synthase in colorectal cancer

(2015) Z. Sun et al.   Clinical & Translational Oncology

MicroRNA Profile in Response to Doxorubicin Treatment in Breast Cancer

(2015) Eduardo Tormo et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

MicroRNA-197 reverses the drug resistance of fluorouracil-induced SGC7901 cells by targeting mitogen-activated protein kinase 1

(2015) HAI-LIN XIONG et al.   Molecular Medicine Reports

MiRNA-149 modulates chemosensitivity of ovarian cancer A2780 cells to paclitaxel by targeting MyD88

(2015) Yueping Zhan et al.   Journal of Ovarian Research

Salinomycin increases chemosensitivity to the effects of doxorubicin in soft tissue sarcomas

(2013) Sven-T Liffers et al.   BMC CANCER

miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes

(2012) Dan-Xia Zhu et al.   CARCINOGENESIS

Variant 1 of KIAA0101, overexpressed in hepatocellular carcinoma, prevents doxorubicin-induced apoptosis by inhibiting p53 activation

(2012) Lijuan Liu et al.   HEPATOLOGY

TRAIL and Doxorubicin Combination Induces Proapoptotic and Antiangiogenic Effects in Soft Tissue Sarcoma In vivo

(2010) S. Wang et al.   CLINICAL CANCER RESEARCH

Dose- and time-dependent effects of doxorubicin on cytotoxicity, cell cycle and apoptotic cell death in human colon cancer cells

(2010) Regine Lüpertz et al.   TOXICOLOGY